IFEZ, Hanlim Pharmaceutical e Incheon TP firman MOU para startups bio

The Incheon Free Economic Zone Authority, Hanlim Pharmaceutical, and Incheon Technopark (ITP) firmó un business acuerdo on the 22nd to discover and nurture startups in the bio sector.

Under this acuerdo, the instituciones plan to identify startups with technologies demanded by the industria and apoyo product validation and comercialización.

The key contents of the acuerdo include discovering and fostering innovador startups through Hanlim Pharmaceutical's demand tecnología identification and cooperative partner programas, establishing a cooperative framework to apoyo on-site validation for startups, and providing continuous crecimiento apoyo through linkage with Incheon Startup Park apoyo programas.

Hanlim Pharmaceutical is a leading company specializing in hypertension, osteoporosis, and producto farmacéutico oftálmicos, ranking first nacionalally in producto farmacéutico oftálmico producción capacity.

In June of el año pasado, la empresa registró as an accelerator (startup planner) to focus on investing in and nurturing bio startups and promoting co-crecimiento, participating in investigación conjunta and desarrollo for global pharmaceutical desarrollo as a strategic investor (SI).

En particular, after signing an inversión acuerdo worth KRW 15 billion with Incheon Startup Park resident company RudaCure Inc., Hanlim Pharmaceutical ha sido actively apoyoing the desarrollo of RCI001, the tratamiento de la enfermedad de ojo seco.

전자신문